GZMM
protein-codinggranzyme M, the group of Granule associated serine proteases of immune defence
Gene summary
Human natural killer (NK) cells and activated lymphocytes express and store a distinct subset of neutral serine proteases together with proteoglycans and other immune effector molecules in large cytoplasmic granules. These serine proteases are collectively termed granzymes and include 4 distinct gene products: granzyme A, granzyme B, granzyme H, and the protein encoded by this gene, granzyme M. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~5.9 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
No GenCC data available for this gene.
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to GZMM variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_005317.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 2 | 1 | 1 | 4 | ||
| missense | 45 | 1 | 2 | 48 | ||
| nonsense | 0 | |||||
| start loss | 0 | |||||
| frameshift | 0 | |||||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 0 | 0 | 47 | 2 | 3 | 52 |
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_005308.2 | 5 | MANE Select | |
| Ensembl | ENSP00000264553.1 | 5 | MANE Select | |
| RefSeq | NP_001245280.2 | 4 | Standard | |
| Ensembl | ENSP00000476255.2 | 4 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Innate Immune System
- Immune System
- Initial triggering of complement
- Complement cascade
- Alternative complement activation
Biological Process
- T cell mediated cytotoxicity
- proteolysis
- apoptotic process
- cell death
- cytolysis
Molecular Function
- serine-type endopeptidase activity
- protein binding
- serine-type peptidase activity
Cellular Component
- extracellular region
- membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000264553
- Coding exons
- 5
- Length
- 5886
- Individuals with no LoFs
- 125594
- Homozygous LoFs
- 2
- Heterozygous LoFs
- 21
- Defined
- 125617
- p
- 0.0000916
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | -0.0733 | 166 | 163 | 1.02 | 0.0000108 | 1596 |
| Missense (PolyPhen) | 61 | 55.157 | 1.1059 | 577 | ||
| Synonymous | -1.00 | 86 | 74.9 | 1.15 | 0.00000511 | 568 |
| Loss of Function | 1.22 | 4 | 7.62 | 0.525 | 3.25e-7 | 89 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.000062 | 0.000062 | rare |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00012 | 0.00011 | rare |
| Finnish | 0.00032 | 0.00028 | rare |
| European (Non-Finnish) | 0.000032 | 0.000026 | rare |
| South Asian | 0.00044 | 0.00033 | rare |
| Other | 0.00020 | 0.00016 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Cleaves peptide substrates after methionine, leucine, and norleucine. Physiological substrates include EZR, alpha- tubulins and the apoptosis inhibitor BIRC5/Survivin. Promotes caspase activation and subsequent apoptosis of target cells. {ECO:0000269|PubMed:18523284, ECO:0000269|PubMed:20406824}.;
Intolerance Scores
- RVIS EVS
- 0.98
- RVIS percentile EVS
- 90.38
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.189
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |